samedan logo
 
 
 
spacer
home > ebr > spring 2004 > protein antigens for therapeutic and diagnostic antibodies biodevelopment and manufacturing
PUBLICATIONS
European Biopharmaceutical Review

Protein Antigens for Therapeutic and Diagnostic Antibodies Biodevelopment and Manufacturing

The ability to generate specific antibodies to specific defined antigens is now regarded as one of the cornerstone techniques in biotechnology. From research tools to cancer therapeutics, the legacy of Kohler and Milstein by their development of monoclonal hybridoma antibody technologies has been instrumental in shaping the biopharmaceutical industry (1). The generation and production of customised antibodies is a now a multi-billion dollar market, fuelled by the successful development of a new generation of antibody-based therapies for disease afflictions such as breast cancer (Herceptin®, Genentech), acute myeloid leukaemia (Mylotarg®, Wyeth), rheumatoid arthritis and Crohn's disease (Remicade®, Centocor)

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Richard Buick, Senior Scientist at Fusion Antibodies Ltd and Christopher Scott, Lecturer in Biomolecular Science at the School of Pharmacy, Queen's University Belfast

Richard Buick is a Senior Scientist at Fusion Antibodies Ltd and is involved with the development of novel antibody-based diagnostic and therapeutic technologies. He is also working towards his PhD in conjunction with the Department of Immunology at Queen's University Belfast (QUB).


Christopher Scott was appointed as Lecturer in Biomolecular Sciences for the School of Pharmacy at the Queen's University Belfast (QUB) in 2003. He has both academic and industrial post-doctoral experience in protein and antibody engineering.

spacer
Richard Buick
spacer
spacer
spacer
Christopher Scott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Joining forces against SARS-CoV-2

Laupheim, Germany and Milford, MA, USA, October 08, 2020 - Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase 3 clinical trial.
More info >>

White Papers

Investigator Portals: Facilitating and Streamlining Communication & Collaboration with Study Sites

ArisGlobal

ArisGlobal LLC Investigator site personnel are often frustrated with the lack of transparency and communication with their sponsors, leading to significant dissatisfaction and withdrawal from current and future studies. The adoption of investigator portals gives sponsors a platform that fosters collaboration and improves site management. Learn about five key areas of sponsor-investigator site interactions deserving of electronic communication and collaboration. Technology and design aspects are also covered.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement